AXSM Axsome Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1579428 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY54.2%
TTM net income YoY31.5%
TTM EPS YoY35.1%
Revenue 3-yr CAGR57.0%
Net income 3-yr CAGR—
Margins
Gross margin93.2%
Operating margin-17.5%
Net margin-18.2%
FCF margin-9.5%
EBITDA margin-17.4%
Returns
ROE-175.6%
ROA-21.0%
ROIC (approx.)—
Asset turnover1.16x
Leverage & solvency
Liabilities / assets87.2%
Debt / equity1.78x
Current ratio1.42x
Interest coverage22.43x
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $638.50M | $385.69M |
| Cost of revenue | $47.48M | $33.30M |
| Gross profit | $591.02M | $352.39M |
| R&D expense | $183.28M | $187.08M |
| SG&A expense | $570.60M | $411.36M |
| Operating income | -$166.76M | -$280.56M |
| Interest expense | -$15.93M | -$21.58M |
| Pretax income | -$183.70M | -$287.13M |
| Income tax | -$530,000 | $85,000 |
| Net income | -$183.17M | -$287.22M |
| EBITDA | -$166.26M | -$280.03M |
| EPS (basic) | -3.68 | -5.99 |
| EPS (diluted) | -3.68 | -5.99 |
| Weighted avg. shares (diluted) | 49.75M | 47.91M |
| Balance sheet | ||
| Cash & equivalents | $322.93M | $315.35M |
| Receivables | $224.46M | $142.00M |
| Inventory | $27.94M | $15.73M |
| Current assets | $588.99M | $485.06M |
| PP&E, net | $562,000 | $584,000 |
| Goodwill | $12.04M | $12.04M |
| Intangibles | $40.52M | $46.89M |
| Total assets | $689.80M | $568.50M |
| Current liabilities | $378.84M | $230.10M |
| Short-term debt | $70.00M | $0 |
| Long-term debt | $117.75M | $180.71M |
| Total debt | $187.75M | $180.71M |
| Total liabilities | $601.51M | $511.48M |
| Shareholders' equity | $88.30M | $57.02M |
| Net debt | -$135.19M | -$134.64M |
| Shares outstanding | 50.88M | 48.67M |
| Cash flow statement | ||
| Operating cash flow | -$93.41M | -$128.41M |
| Capital expenditure | $480,000 | $270,000 |
| Free cash flow | -$93.89M | -$128.68M |
| Investing cash flow | -$480,000 | -$270,000 |
| Financing cash flow | $101.47M | $57.84M |
| Depreciation & amortization | $503,000 | $532,000 |
| Stock-based compensation | $93.75M | $85.22M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.